# Correlation of differential expression of MEG3 lnc-RNA with biochemical parameters in Type-II diabetic patients with and without diabetic kidney disease

**Authors:** Huma Saeed Khan, Uzma Zafar, Waqar Ahmad, Saba Khaliq

PMC · DOI: 10.12669/pjms.42.1.12591 · Pakistan Journal of Medical Sciences · 2026-01-01

## TL;DR

This study found that MEG3 lnc-RNA is more active in type-II diabetic patients with kidney disease and may serve as a future diagnostic tool.

## Contribution

The paper identifies a novel correlation between MEG3 lnc-RNA expression and biochemical markers in diabetic kidney disease.

## Key findings

- MEG3 lnc-RNA expression was significantly higher in diabetic kidney disease patients compared to others.
- MEG3 correlated positively with fasting insulin in DKD patients and negatively in DM patients.
- MEG3 showed a negative correlation with urinary creatinine in DKD patients.

## Abstract

Diabetic kidney disease (DKD) is a complication of type-II diabetes mellitus (DM) leading to significant morbidity and mortality. Long non-coding RNAs (lnc-RNAs) are a class of ribonucleic acid that exert their effects in development of such complications through epigenetic modifications. The study was conducted with the objectives to compare the relative expression of MEG3 lnc-RNA in patients of Type-II DM, with and without DKD, and to determine the correlation of this expression with blood and urine biomarkers.

A cross-sectional study was conducted at the University of Health Sciences, Lahore, after ethical approval from December 2022 till October 2023. Study participants were recruited in three groups having DKD, Type-II DM and healthy individuals, each group having 68 participants. Analysis of blood and urine biomarkers was performed. MEG3 lnc-RNA expression was determined by using RT-PCR. Kruskal Wallis test, post hoc Mann-Whitney U test and Spearman’s correlation were used for data analysis.

The relative expression of MEG3 lnc-RNA was significantly higher in the DKD group (median=3.83, IQR=1.22-3.83) as compared to the DM (median= 2.22, IQR= 0.49-3.12) and healthy groups (median= 1.97, IQR= 1.17-1.97) with a p-value of 0.002. There was a significant positive correlation between MEG3 expression and fasting insulin in the DKD group, a significant negative correlation with fasting insulin in the DM group, a significant negative correlation with serum very low-density lipoproteins in the healthy group, and a significant negative correlation between MEG3 lnc-RNA expression and urinary creatinine in the DKD group.

MEG3 lnc-RNA has a higher relative expression in the patients suffering from DKD in the local diabetic population. In future, it may be used as a diagnostic marker as well as for inducing epigenetic modification through RNA transfection.

## Linked entities

- **Genes:** MEG3 (maternally expressed 3) [NCBI Gene 55384]
- **Diseases:** Type-II diabetes mellitus (MONDO:0005148), diabetic kidney disease (MONDO:0005016)

## Full-text entities

- **Genes:** DLK1 (delta like non-canonical Notch ligand 1) [NCBI Gene 8788] {aka DLK, DLK-1, Delta1, FA1, PREF1, Pref-1}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, DHCR7-DT (DHCR7 divergent transcript) [NCBI Gene 129810502] {aka AP, lnc}, MEG3 (maternally expressed 3) [NCBI Gene 55384] {aka FP504, GTL2, LINC00023, Lnc-DLK1-35, NCRNA00023, PRO0518}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, Meg3 (maternally expressed 3) [NCBI Gene 500717] {aka Gtl2, RGD1566401}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** fibrosis (MESH:D005355), albuminuria (MESH:D000419), glomerulosclerosis (MESH:D005921), inflammation (MESH:D007249), insulin resistance (MESH:D007333), vascular dysfunction (MESH:D002561), end stage renal disease (MESH:D007676), DM (MESH:D003920), carcinoma (MESH:D009369), kidney or endocrine disease (MESH:D007674), Type-II DM (MESH:D003924), DKD (MESH:D003928), impaired glucose tolerance (MESH:D018149)
- **Chemicals:** very low-density (-), urea (MESH:D014508), Trizol (MESH:C411644), streptozocin (MESH:D013311), lipid (MESH:D008055), reactive oxygen species (MESH:D017382), creatinine (MESH:D003404), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** A1C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12927110/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12927110/full.md

---
Source: https://tomesphere.com/paper/PMC12927110